Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In this report, the utility of a commonly used interspecies scaling method to predict the systemic clearance (CL) of therapeutic proteins in humans was evaluated. Based on analysis of a pharmacokinetic data set of 34 therapeutic proteins, including 12 monoclonal antibodies (mAbs) and Fc fusion proteins, human CL can generally be predicted reasonably well with simple allometric scaling and a fixed exponent of 0.8:∼95% of the cases predicted values within 2‐fold of the observed values when using CL data from multiple species, or∼90% simply using CL from monkeys. Specific to mAbs/Fc fusion proteins, scaling from monkey CL using a fixed exponent of 0.8 gave an excellent prediction; all predicted CL values were within 2‐fold of the corresponding observed values. Compared with the simple allometric scaling method that uses a fitted exponent from CL data of ≥3 preclinical species, the fixed exponent approach with 1–2 preclinical species is simple, resource‐saving and minimizes systematic bias. Together with its overall satisfactory prediction accuracy, especially in the absence of non‐linear pharmacokinetics and species‐specific clearance mechanisms, this fixed exponent method affords a viable alternative to other published allometric methods, including the Rule of Exponents (ROE). Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · cited 9×
“Fc mutants that fail to bind FcRn are cleared rapidly from the circulation and the clearance of IgG is significantly higher in mice lacking expression of functional FcRn [3,4].”
BackgroundInfluentialInterspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 4×
“biliary or renal excretion, but not with compounds that exhibit non-linear or species-specific pharmacokinetics [7,8].”
BackgroundMethodInfluentialEgrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00006-7 · Cited by 421 · cited 1×
“RSHZ19 [27] [28] Darbepoetin alfa [45] e”
Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look
Ling, J., Zhou, H., Jiao, Q., & Davis, H. M. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337134 · Cited by 144 · cited 1×
“in a most recent paper (just emerged at the time of the review cycle of our manuscript) [48].”
Background
Cited by
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
“If peptides behave more like proteins that are eliminated through proteolysis, renal filtration, catabolism, and endocytosis, allometric scaling appears to be successful in predicting human PK parameters from preclinical species (22,116).”
BackgroundMethodPharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377
“mAbs) has been reviewed elsewhere (68,71).”
BackgroundDeng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S. (2011) · mAbs · doi:10.4161/mabs.3.1.13799 · Cited by 285
“have made similar recommendations.(7) Our current work expanded our previous work(5) and that of others(6,7) (only bevacizumab and trastuzumab overlapped with the Ling et al.”
MethodResultZheng, Y., Tesar, D. B., Benincosa, L., Birnböck, H., Boswell, C. A., Bumbaca, D., Cowan, K. J., Danilenko, D. M., Daugherty, A. L., Fielder, P. J., et al. (2012) · mAbs · doi:10.4161/mabs.4.2.19387 · Cited by 149
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Huh, Y., Smith, D. E., & Rose Feng, M. (2011) · Xenobiotica · doi:10.3109/00498254.2011.598582 · Cited by 98
“Positive results from human clearance prediction of macro-molecule drugs using allometric scaling have already been reported by several groups (Mordenti et al., 1991, Mahmood, 2004, Mahmood, 2009b, Ling et al., 2009, Wang and Prueksaritanont, 2010).”
BackgroundResultInfluentialWang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
Dostalek, M., Prueksaritanont, T., & Kelley, R. F. (2017) · mAbs · doi:10.1080/19420862.2017.1323160 · Cited by 45
Self-citation
Metadata
- Authors
- Wang, W., & Prueksaritanont, T.
- Venue
- Biopharmaceutics & Drug Disposition
- Publisher
- Wiley
- Published
- 2010-04-08
- Volume
- 31
- Issue
- 4
- Pages
- 253-263
- ISSN
- 0142-2782 (ISSN-L)
- 1099-081X
- OpenAlex
- W2075068090
- Cited by
- 105
- References
- 4
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.